Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Let’s dive deeper into the company’s earnings to understand the factors driving its growth.
Abbott Laboratories (NYSE:ABT) reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items, and reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58, which suggests management’s confidence in the company’s ability to sustain growth for the remainder of the year.
Bull Case
One of the most prominent highlights of the quarter for investors is Abbott Laboratories’ (NYSE:ABT) diagnostics segment. The company’s cancer diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard. The quarter’s earnings report corroborates this, as sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company’s strongest performers during the quarter.
Analysts agree with this sentiment. William Blair stated that the company’s cancer diagnostics results should improve sentiment around the Exact Sciences acquisition, with growth in medical devices helping offset concerns surrounding hospital procedure volumes.
The firm reiterated an Outperform rating on the shares and noted that its shares rose over 10% on fiscal Q2 results, which helps relieve the concerns surrounding the recent Exact Sciences acquisition and medtech end markets and signals an improving nutrition business. It told investors in a research note that all of these updates were positive and should compound with pipeline products for even better results in H2 2026 and into FY27.
What Investors Should Watch Next
While Abbott Laboratories’ (NYSE:ABT) outlook remains encouraging, a meaningful portion of its expected growth acceleration in the second half of 2026 depends on the successful commercialization of several pipeline products. William Blair highlighted the key pipeline products for the company that investors should watch next, including the launch of Amulet 360 late in the year or early in 2027, the ramping-up launch of Volt in the U.S. and TactiFlex Duo OUS, and the potential for Libre reimbursement expansion.
Management has expressed confidence that sales and earnings growth will accelerate in the second half of 2026. While this outlook is supported by improving momentum across multiple business segments, investors will need to see that acceleration materialize over the coming quarters. Notably, Abbott Laboratories (NYSE:ABT) reaffirmed rather than raised its full-year comparable sales growth guidance of 6.5% to 7.5%, suggesting that management remains prudent despite its strong second-quarter performance.
Similarly, worldwide nutrition sales in the quarter dropped 3.1% on a reported basis and 3.6% on a comparable basis in the second quarter, reflecting the effects of lower sales volumes compared to the previous year and the impact of strategic pricing actions that were implemented in fiscal Q4 2025. These pricing actions, along with new product launches, are contributing to improving performance, as nutritional sales rose $127 million on a sequential basis compared to fiscal Q1 2026. Investors should, however, keep an eye out to ensure that these trends continue improving.
What Does The Hedge Fund Sentiment Say?
According to Insider Monkey’s database of 1,022 hedge funds, hedge fund sentiment for the stock has improved moderately from last quarter, going from 71 in fiscal Q4 2025 to 73 in fiscal Q1 2026. While the increase is modest, it suggests that institutional investors continue to maintain confidence in Abbott Laboratories’ (NYSE:ABT) long-term growth prospects following its strong quarterly performance.
Abbott Laboratories (NYSE:ABT) currently trades at a forward P/E of 18.69 at a 3.57% discount to the sector. The valuation may appeal to investors seeking exposure to a diversified healthcare company that is simultaneously benefiting from strength in diagnostics, medical devices, and a growing product pipeline.
While we acknowledge the risk and potential of EWABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center